18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Miltefosine for new world cutaneous leishmaniasis.

      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

      Administration, Oral, Adult, Animals, Antiprotozoal Agents, adverse effects, therapeutic use, Colombia, Double-Blind Method, Drug Tolerance, Female, Guatemala, Humans, Leishmania, drug effects, Leishmaniasis, Cutaneous, drug therapy, Male, Patient Compliance, Phosphorylcholine, analogs & derivatives, Treatment Outcome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo-controlled study of miltefosine therapy (2.5 mg/kg per day orally for 28 days) against cutaneous leishmaniasis in Colombia and Guatemala. In regions in Colombia where Leishmania vianna panamensis is common, the per-protocol cure rates for miltefosine and placebo were 91% (40 of 44 patients) and 38% (9 of 24). These values are similar to historic values for the antimony standard of care and placebo. In regions in Guatemala where L. v. braziliensis and L. mexicana mexicana are common, the per-protocol cure rates were 53% (20 of 38) for miltefosine and 21% (4 of 19) for placebo. The miltefosine rate was lower than historic antimony cure rates of >90%. Miltefosine was well tolerated. Miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leishmaniasis due to L. v. braziliensis in Guatemala.

          Related collections

          Author and article information

          Journal
          15127339
          10.1086/383321

          Comments

          Comment on this article